Retirement Systems of Alabama Makes New $21.37 Million Investment in Avantor, Inc. (NYSE:AVTR)

Retirement Systems of Alabama purchased a new position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 825,842 shares of the company's stock, valued at approximately $21,365,000. Retirement Systems of Alabama owned approximately 0.12% of Avantor at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of AVTR. Hantz Financial Services Inc. boosted its stake in Avantor by 2.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company's stock valued at $644,000 after purchasing an additional 503 shares during the period. Intech Investment Management LLC raised its position in Avantor by 1.8% in the second quarter. Intech Investment Management LLC now owns 29,068 shares of the company's stock worth $616,000 after purchasing an additional 514 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Avantor by 0.3% during the 2nd quarter. Arizona State Retirement System now owns 186,567 shares of the company's stock worth $3,955,000 after buying an additional 528 shares during the period. Veracity Capital LLC increased its position in shares of Avantor by 1.0% during the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company's stock worth $1,355,000 after purchasing an additional 543 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of Avantor by 2.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 26,921 shares of the company's stock valued at $571,000 after acquiring an additional 733 shares during the last quarter. Institutional investors own 95.08% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on AVTR shares. Royal Bank of Canada reissued an "outperform" rating and set a $34.00 price target on shares of Avantor in a research note on Thursday, September 26th. Barclays lowered their target price on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Friday, October 25th. UBS Group cut their price objective on Avantor from $30.00 to $29.00 and set a "buy" rating on the stock in a report on Tuesday, October 8th. Robert W. Baird dropped their price target on Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 28th. Finally, Wells Fargo & Company reduced their target price on shares of Avantor from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Monday, October 28th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $27.69.

Avantor Price Performance

NYSE AVTR traded down $0.20 during trading on Friday, reaching $22.33. The company's stock had a trading volume of 3,578,948 shares, compared to its average volume of 6,472,614. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The firm has a fifty day moving average of $22.47 and a 200 day moving average of $23.53. The stock has a market capitalization of $15.20 billion, a PE ratio of 48.54, a P/E/G ratio of 2.75 and a beta of 1.29. Avantor, Inc. has a one year low of $19.59 and a one year high of $28.00.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.